Stella Dolci

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

Martine Piccart, Eileen Holmes, José Baselga et al. · Journal of Clinical Oncology · 2015 · 374 citations · Full text

Medicine, Oncology, Pharmacology +17

HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.

Angelo Di Leo, David Gancberg, Denis Larsimont et al. · PubMed · 2002 · 267 citations

Medicine, Cancer Biology, Oncology +15

Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries

Kamal S. Saini, Catherine Taylor, Antonio J. Ramírez et al. · Annals of Oncology · 2011 · 212 citations · Full text

Medicine, Oncology, Breast Oncology +13

Disease-Free Survival According to Degree of <i>HER2</i> Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial

Mitch Dowsett, Marion Procter, Worta McCaskill‐Stevens et al. · Journal of Clinical Oncology · 2009 · 185 citations · Full text

Medicine, Cancer Biology, Oncology +16

Phase III Trial Comparing Two Dose Levels of Epirubicin Combined With Cyclophosphamide With Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer

Martine Piccart, Angelo Di Leo, M. Beauduin et al. · Journal of Clinical Oncology · 2001 · 163 citations

Medicine, Oncology, Pharmacotherapy +11